SCHEMBL2188488

SCHEMBL2188488

O=C1CC2(CCNCC2)c2cc(Cl)ccc21

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PGR P06401 2/20 0.40
AKR1B1 P15121 3/20 0.40
AKR1A1 P14550 2/20 0.40
PPOX P50336 1/20 0.40
HTR2C P28335 6/20 0.39
HTR2A P28223 4/20 0.39
HTR2B P41595 3/20 0.39
F7 P08709 1/20 0.37
PARP1 P09874 1/20 0.37
F3 P13726 1/20 0.37
PARP10 Q53GL7 1/20 0.37
CES1 P23141 1/20 0.37
DRD2 P14416 1/20 0.37
PDE7A Q13946 1/20 0.36
CMA1 P23946 1/20 0.36
AHR P35869 1/20 0.36
MAPT P10636 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
AKT1 P31749 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25360261 0.78 PDK2 (0.37) AKR1B1AKR1A1PPOXHTR2CHTR2A
SCHEMBL11819586 0.77 AKR1B1 (0.40) PGRAKR1B1AKR1A1PPOXF7
SCHEMBL394558 0.77 HRH3 (0.41) HTR2CHTR2AHTR2BDRD2
Hydrochloric Acid SCHEMBL2101720 0.76 HRH3 (0.41) HTR2CHTR2AHTR2BDRD2
SCHEMBL22493790 0.75 HTR2C (0.42) PPOXHTR2CHTR2AHTR2BF7
SCHEMBL21856169 0.75 F7 (0.44) PPOXHTR2CHTR2AHTR2BF7
SCHEMBL29506005 0.75 F7 (0.44) PPOXHTR2CHTR2AHTR2BF7
Hydrochloric Acid SCHEMBL21855899 0.74 HTR2C (0.41) PPOXHTR2CHTR2AHTR2BF7
SCHEMBL26174678 0.73 JAK2 (0.48)
SCHEMBL13001434 0.73 ALDH1A1 (0.40) DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250195483-A1 SPIRO PIPERIDINE DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME VERTEX PHARMA (US) 2025-06-19 US disclosed
EP-4476207-A1 SPIRO PIPERIDINE DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME Vertex Pharmaceuticals Incorporated (US) 2024-12-18 EP disclosed
WO-2023154314-A1 SPIRO PIPERIDINE DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-08-17 WO disclosed
WO-2023154314-A1 SPIRO PIPERIDINE DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-08-17 WO disclosed
US-20140031378-A1 INSECTICIDAL SPIRONINDANE DERIVATIVES SYNGENTA CROP PROTECTION LLC 2014-01-30 US disclosed
US-8354423-B2 Insecticidal spironindane derivatives SYNGENTA CROP PROTECTION LLC (US) 2013-01-15 US disclosed
EP-1697327-B1 INSECTICIDAL SPIROINDANE DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2011-07-13 EP disclosed
US-20080306101-A1 Insecticidal Spironindane Derivatives SYNGENTA PARTICIPATIONS AG (CH) 2008-12-11 US disclosed
EP-1697327-A1 INSECTICIDAL SPIROINDANE DERIVATIVES Syngenta Participations AG (CH) 2006-09-06 EP disclosed
WO-2005058836-A1 INSECTICIDAL SPIROINDANE DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2005-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250195483-A1 SPIRO PIPERIDINE DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME APOL1, PNLIP, SAAL1 PGR 4384/4885AKR1B1 773/4885AKR1A1 927/4885
US-20080306101-A1 Insecticidal Spironindane Derivatives NR1D1, NR1D2, NR1I3 PGR 1289/4885AKR1B1 67/4885AKR1A1 36/4885
US-20140031378-A1 INSECTICIDAL SPIRONINDANE DERIVATIVES NR1D1, NR1D2, NR1I3 PGR 1289/4885AKR1B1 67/4885AKR1A1 36/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.